5 Best Emerging Markets Stocks to Buy According to Analysts

Page 5 of 5

1. Zai Lab Limited (NASDAQ:ZLAB)

Average Analyst Price Target as of February  27: $60.52

Upside Potential as of February 27: 169.10%

Number of Hedge Fund Holders: 15

Shanghai, China-based Zai Lab Limited (NASDAQ:ZLAB) is a commercial-stage, global biopharmaceutical company focused on medicines for oncology, autoimmune disorders, infectious diseases, and neurological disorders.

On February 27, Zai Lab Limited (NASDAQ:ZLAB) released its financial results for Q4 2023. Its revenue, at $66 million, missed consensus estimates by $5.6 million, while normalized EPS, at -$0.98, missed estimates by $0.11.

On December 14, Morgan Stanley initiated coverage of Zai Lab Limited (NASDAQ:ZLAB) shares with a price target of $47.5 per share and an ‘Overweight’ rating. The target price represents a potential upside of 111.20%.

You may also like to read 11 Best Brewery and Distillery Stocks to Buy Now and 13 Best Diversified Dividend Stocks To Invest In

Page 5 of 5